Hobbensiefken G, Driller B, Studtmann V, Kunz K, Lehrbach G
Institut für Anästhesiologie und operative Intensivmedizin, Diakoniekrankenhaus Rotenburg, Wümme.
Unfallchirurgie. 1996 Dec;22(6):248-52.
Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.
II型肝素诱导的血小板减少症（HIT II）是小剂量肝素预防性治疗期间最严重的并发症。5例病例显示了这种免疫介导的血栓栓塞性疾病危及生命的后果。为改善预后，在通过实验室检查确定诊断之前尽早开始治疗最为重要。首选治疗药物是低分子肝素类药物Orgaran。发生过一次HIT II的患者，终身禁用低分子肝素和普通肝素。
